Anti-inflammatory Small Drug as Adjunctive Therapy to Improve Glucometabolic Variables in Obese, Insulin-Resistant Type 2 Diabetic Patients

 描述（由申请方提供）：个体白细胞群在2型糖尿病（T2D）和免疫代谢中的作用通常代表了更好地理解T2D发病机制的重要知识空白。新出现的证据表明，某些白细胞群是T2D相关炎症的重要联系。这项新颖的创新性临床试验将测试白细胞选择性抗炎小分子药物作为连续治疗在改善肥胖、胰岛素抵抗的2型糖尿病受试者的胰岛素敏感性方面的疗效。这项试验也提供了一个首次的机会，以更好地了解特定白细胞群体在2型糖尿病中的作用。该药物的临床特征表明，它将具有良好的耐受性，副作用很少（如果有的话），并且存在可以间接测量其体内活性的简单方法。

 DESCRIPTION (provided by applicant): The role of individual leukocyte populations in type 2 diabetes (T2D) and immunometabolism in general represent important gaps in knowledge to better understand the etiopathogenesis of T2D. Emerging evidence indicates that certain leukocyte populations serve as an important nexus of T2D-associated inflammation. This novel and innovative clinical trial will test the efficacy of a leukocyte-selective anti-inflammatory small drug as adjunctive therapy in improving insulin sensitivity in obese, insulin-resistant type 2 diabetic subjects. This trial also offers a first-in-kind opportunity to better understand the role of specific leukocyte populations in type 2 diabetes. The drug’s clinical profile suggests that it will be well-tolerated with few, if any, side effects, and the existence of simple methods that can indirectly measure its activity in vivo.